Regeneron Pharmaceuticals Inc (REGN) was Downgraded by Robert W. Baird to ” Neutral” while Lowering the Price Target of the company shares to $ 448 from a previous price target of $505 . Earlier the firm had a rating of “Outperform ” on the company shares. Robert W. Baird advised their investors in a research report released on Aug 5, 2016.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.82 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.65. The company had revenue of $1213.00 million for the quarter, compared to analysts expectations of $1237.52 million. The company’s revenue was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.89 EPS.
Regeneron Pharmaceuticals Inc closed down -7.97 points or -1.81% at $433.4 with 20,26,865 shares getting traded on Thursday. Post opening the session at $443.29, the shares hit an intraday low of $417.5 and an intraday high of $443.99 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
In a different news, on Aug 1, 2016, Joseph L Goldstein (director) sold 2,125 shares at $425.00 per share price. According to the SEC, on May 25, 2016, Arthur F Ryan (director) sold 1,000 shares at $396.64 per share price. On May 19, 2016, Plew Daniel P Van (EVP & General Mgr Industrial O) sold 4,413 shares at $385.77 per share price, according to the Form-4 filing with the securities and exchange commission.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.